Introduction
The refractory nature of cancer to many standard therapies has led to substantial efforts to achieve immune control. Here we propose a mechanism by which the immunodominance hierarchy that allows a growing tumor to escape from immune surveillance may be broken. We focus on mitigating the deleterious effects of immunodominance and on achieving an effective strategy in the face of central and peripheral tolerance. Our approach captures the recognition characteristics between the T cell receptors (TCRs) and tumor, the primary dynamics due to TCR resource competition, and elimination of tumor cells by TCRs. The hypothesis that polytopic vaccination induces independent selection of T cells for each epitope of the vaccine in distinct lymph nodes is consistent with the experimental data. Polytopic administration of a therapeutic cancer vaccine may sculpt a broader immune response and mitigate immunodominance. We suggest that by inducing a T cell response to each cancer-associated epitope in a distinct lymph node, vaccine efficacy is increased and immunodominance is reduced. Whether the cancerassociated epitopes are related or unrelated, polytopic vaccination appears to be a promising therapeutic strategy. Our immune system protects us against a broad spectrum of possible cancers [2] [3] [4] . Work with interferon-γ receptor knockout mice, which exhibited extremely high incidences of spontaneous cancers, suggests a daily combat of cancers by the immune system [5, 6] . Several limitations of the cellular immune system have been reported, however, that stem from the cross-reactivity of T cell receptors. One obstacle to a robust immune response is immunodominance, in which dominant cancer-associated epitopes suppress the generation of CTL (cytotoxic T lymphocyte) activity toward other non-dominant epitopes of the same cancerous cell [7] . Immunodominance may thereby prevent the development of an immune responses to more than the dominant epitope among the multiple tissue-specific and tissue-associated cancer antigens [8] . Immunodominance may also inhibit development of an immune response to the new tissue-specific antigens that develop during the course of tumor progression [9] . Many experimental observations are consistent with the hypothesis that outgrowth of patient's tumors reflects Darwinian selection of tumor cells that have acquired escape mechanisms from immune recognition [5, [10] [11] [12] . It remains a challenge to fully elucidate the mechanisms holding back tumor-specific immunity [13] .
A given cancer typically has several tissue-specific or tissue-related epitopes that are recognized by the immune system. Typically, one of these epitopes generates the most strong immune response, i.e. is dominant. This dominant epitope inhibits the immune response to the subdominant epitopes and this immunodominance phenomenon reduces the diversity of the immune response to such a disease [7] . The essence of this immunodominance phenomenon is competition of TCRs for epitope on antigen presenting cells [7, 14] . This immunodominance phenomenon is important to understand because it can render a multivalent vaccine effectively monovalent.
Immunodominance is one general mechanism by which cancer cells may escape, either by mutation of the dominant epitope or by loss of the MHC class I allele that expresses the dominant epitope [15] . Cross-presentation of the lost dominant epitope on surrounding cells often sustains the futile immune response [8] . Indeed, cancerous cells of many types are exceptionally adept at evading the immune response [4] . It has been noticed that not only the quantity, but also the quality of the T cell response induced by therapeutic vaccination is important for clinical efficacy [16] . For these reasons, it has been suggested that multiple immune-stimulation strategies will be necessary to avoid escape from the immune response by cancer [4, 17] .
By sculpting the diversity of the effector T cell receptor (TCR) repertoire, immune evasion of tumor cells can be reduced. Here we propose a mechanism by which the immunodominance hierarchy that allows a growing tumor to escape from immune surveillance may be broken. Our approach captures the essence of the interaction between TCRs and antigenic epitopes and the primary selection dynamics of TCRs within lymph nodes due to TCR resource competition [18] .
The Polytopic Vaccination Experiment
Immunodominance implies that the immune response to multiple cancerspecific epitopes may be incomplete because the response may be directed primarily against the dominant epitope. That tumors are suppressed by in vitro-derived T cells directed against two or more epitopes [19] [20] [21] suggests the failure may be in the development of the immune response rather than in the intrinsic lytic ability of the T cells.
One suggestion for breaking the effectively monovalent response to a multivalent cancer vaccine is to inject the different vaccine epitopes or strains in different physical regions of the patient [8] . When this is done for the 1591-A/B system, a T cell response is generated against the dominant epitope A, and a response is generated against the subdominant epitope B as well [19] . Specifically, cells expressing the A epitope are lysed by vaccine A or by vaccines AB and B injected in the same site. Cells expressing only the subdominant B epitope are not. Cells expressing only the subdominant B epitope are lysed by vaccine B or by vaccines AB and B injected in different sites, not by vaccine A nor by vaccines AB and B injected in the same site. Thus, it appears that vaccination with individual tumor epitopes at separate sites rather than with multiple epitopes at one site may be needed to prevent tumor escape and recurrence of cancer.
These experiments have not been widely cited by other researchers. Moreover the mechanism for the reduction in immunodominance has not been described. We seek to shed some light on the possible mechanism by polytopic vaccination may reduce immunodominance. With such a mechanism in hand, further experiments to confirm or refute the hypothesis can be performed.
We investigate the hypothesis that polytopic, or multi-site, administration of a therapeutic cancer vaccine may sculpt a broader immune response. We here study the proposed mechanism of polytopic vaccination by developing a sequence-level model of immune response to polytopic cancer vaccines [22] . Our approach captures the recognition characteristics between the T cell receptors (TCRs) and tumor, the primary dynamics due to TCR resource competition, and elimination of tumor cells by effector TCRs. We focus the discussion on reducing the deleterious effects of immunodominance and on strategies that may achieve an effective strategy in the face of central and peripheral tolerance. The model we develop complements the long and difficult process of experimental vaccine development. The model takes explicit account of the dynamics of the 10 8 different T-cell sequences that exist within an individual.
We study the interactions between the response of the immune system to the various cancer tissue-specific epitopes [23] [24] [25] . For specificity, we consider V = 2 or V = 4 tissue-specific epitopes. Each antigen is an epitope of 9 amino acids [26] . The primary immune response lasts for 10 rounds of T cell division. After this period of time, there is a high concentration of T cell receptors specific for the tissue-specific epitopes. In single-site vaccination, the immune system simultaneously shapes the T cell repertoire based upon all epitopes. In polytopic vaccination, on the other hands, the immune system responds to each epitope independently in distinct lymph nodes, and only after some number of days is there a significant mixing of the evolved T cell repertoires. We denote the day after which the T cell repertoires for the V distinct epitopes begin to compete as mixing day. We present results for a range of this parameter, mixing day.
The dependence on the spatial separation of the vaccination sites is an interesting question. There are three times to consider. The first is the time it takes for the injected vaccine to localize to the draining lymph node. This is on the order of 1-12 hours [27] . The second is the time for the T cells to grow to such a concentration that they begin to leave the lymph node. This time is known to be 4-5 days [1] . Finally, there is the time it takes the T cells that have left a lymph node to transport along the major lymphatics to the thoracic duct (or right lymphatic duct for lymph fluid from the right upper arm and head), where the T cells then mix with the blood. The characteristic timescale for complete circulation of the lymph system is an additional 4 days [28] . The time for a significant number of T cells to reach the bloodstream from the lymph can be a bit shorter, on the order of 2 additional days, for T cells leaving lymph nodes located closer to the heart [29, 30] . Thus, for vaccination that drains to lymph nodes relatively far from the heart, the time it takes for T cells from different injection sites to mix through the lymph is on the order of 7-9 days. We term this time the "mixing day."
The focus of our study is a comparison of vaccination at distant lymph nodes, e.g. mixing day = 7-9, to vaccination at the same lymph node, e.g. mixing day = 0. Drainage to a specific lymph node can be enhanced in polytopic vaccination by using antigen-bearing dendritic cells [31, 32] . While interactions due to transport can be important for lymph nodes very close together on a lymphatic, for polytopic vaccination we will choose well-separated sites, so that these interactions need not be considered. Typical values of mixing day are shown in Fig. 1 . Values for vaccination that drains to lymph nodes relatively far from the heart are in the range 7-9 days. For an effective polytopic vaccination, we would choose sites such that mixing day is large, e.g. mixing day = 9.
Since immunodominance is a competition of TCRs for alternative epitopes [7, 14] , we capture this effect within our model by the inclusion of multiple, sub-dominant, epitopes for each strain. Immunodominance causes the T cell immune response to sequential exposure to two different epitopes to depend on the order of their presentation. For example, in the 1591 system, where the A epitope is dominant and the B epitope is subdominant, exposure to a mixed vaccine of A and B generates a response primarily against A. Exposure to a single vaccine of B, however, generates a response against B, even if a subsequent vaccine of A and B is given [19] . The same phenomenon occurs in the 8101 AB system [34] . We will model this phenomenon by performing primary responses to vaccines of A, B, or A and B in the same site. The results will be compared to primary vaccination of A and B in separate sites. 
Generalized N K Model
We use a spin glass model to represent the interaction between the T cell receptors and the epitopes [22, 35, 36] . This model captures the essence of the correlated ruggedness of the interaction energy in the variable space, the variables being the T cell amino acid sequences and the identity of the disease proteins, and the correlations being mainly due to the physical structure of the T cell receptors. The random energy model allows study of the sequencelevel dynamics of the immune/antigen system, which would otherwise be an intractable problem at the atomic scale, with 10 4 atoms per T cell receptor, 10 8 antibodies per individual, 6 × 10 9 individuals, and many possible cancer epitopes.
The generalized NK model, while a simplified description of real proteins, captures much of the thermodynamics of protein folding and ligand binding. In this model N is the number of amino acids in a secondary structure, and K is the range of the local interaction. In the model, a specific T cell repertoire is represented by a specific set of amino acid sequences. Moreover, a specific instance of the random parameters within the model represents a specific epitope. An immune response that finds a T cell that produces a T cell receptor with a high affinity constant to a specific epitope corresponds in the model to finding a sequence having a low energy for a specific parameter set. Use of a sequence-level model allows for a broad range of predictions. We can, for example, predict altered peptide ligand experiments [22] . Such a model also allows one to predict the reduced immune response to a mutated cancer antigen. Such a model, therefore, has a broader range of applicability than a model with an ad hoc assumption about the distribution of binding constants.
The generalized NK model for the T cell response considers four different kinds of interactions: interactions within a subdomain of the TCR (U sd ), interactions between subdomains of the TCR (U sd−sd ), interactions between the TCR and the peptide (U pep−sd ), and direct binding interaction between the TCR and peptide (U c ) [22, 36] . A figure of the TCR-peptide MHCI complex is shown in Fig. 2 . The direct interactions are distinguished as resulting from a limited number of "hot spot" interactions. The model returns the free energy (U ) as a function of the TCR (a j ) and epitope (a 
Here M = 6 is the number of TCR secondary structural subdomains, N b = 3 is the number of hot-spot amino acids that directly bind to the TCR, and N CON = 3 is the number of T cell amino acids contributing directly to the binding of each peptide amino acid. N = 9 is the number of amino acids in a subdomain, and K = 4 is the range of local interaction within a subdomain. All subdomains belong to one of L = 5 different types (e.g., helices, strands, loops, turns, and others). 
The binding constant is related to the energy by
We determine the values of a, b in each instance of the ensemble by fixing the geometric average TCR:p-MHC I affinity to be K = 10 4 l/mol and minimum affinity to be K = 10 2 l/mol [37] for the V × N size = V × 10 8 /10 5 = V × 1000 naive TCRs that respond to all V epitopes [37, 38] . This means that for the highest affinity TCR, K fluctuates between 10 5 l/mol and 10 7 l/mol for the different epitopes [39] . The distribution is shown in Fig. 3 .
Specific lysis is a measure of the probability that an activated T cell will recognize an cell that is expressing a particular peptide-MHC I complex. It is given by [22] 
where E/T is the effector to target ratio. The quantity z is the average clearance probability of one TCR:
Note the clearance probability is related to both affinity and clonal sizes. Typical naive values will be approximately 5/1000, and typical values after a primary response will be in the range 0.1 to 1.0, due to the increased copy number of the selected T cells. Specific lysis is a standard measure of the immunological response to a vaccine, which correlates well with vaccine efficacy [40] . On 5 l/mol and 10 7 l/mol, in agreement with experiment [39] . The median upper affinity is 10 6 l/mol the order of 1-3 TCR/peptide-MHCI interactions are enough for killing [41] , and the TCR affinity is highly correlated with proliferation [18, 42] . Binding constants larger than roughly 10 6 l/mol do not increase the lysis, hence the bound in (8).
TCR Selection Dynamics
The cellular immune system performs a search of T cell receptors (TCRs) that recognize antigenic peptide ligands bound to the MHCI molecule. The T cells are activated by ligand binding to the multiple identical TCRs on the T cell membrane [39, 43, 44] . TCRs are constructed from modular elements, and each individual has an approximate diversity of 10 8 different receptors [45] . TCRs undergo rounds of selection for increased avidity [46] [47] [48] [49] . TCRs do not undergo any further mutation during the immune response. Those TCRs that are stochastically selected during the primary response become memory cells [50, 51] . While there may well be other details which affect the T cell selection process, selection for increased affinity has been shown to be an important factor [18, [51] [52] [53] [54] . A schematic of the selection model of the T cell immune system maturation is shown in Fig. 4 .
The naive TCR repertoire is generated randomly from gene fragments. This is accomplished by constructing the TCRs from subdomain pools. Fragments for each of the L subdomain types are chosen randomly from 13 of the 100 lowest energy subdomain sequences. This diversity mimics the known TCR diversity, (13 × L) M ≈ 10 11 [55] . Only 1 in 10 5 naive TCRs responds to any particular antigen, and there are only 10 8 distinct TCRs present at any one point in time in the human immune system [37, 38] , so the primary response starts with a repertoire of N size = 10 3 distinct TCRs. The initial TCR repertoire is redetermined for each realization of the model -this must be done because the U sd that defines the TCR repertoire is different in each instance of the ensemble.
The T cell-mediated response is driven by cycles of concentration expansion and selection for better binding constants. The primary response increases the concentration of selected TCRs by 1000 fold over 10 days, with a rough T cell doubling time of one day [1] . The diversity of the memory sequences is 0.5% of that of the naive repertoire [45] . Thus, while the number of distinct T cells selected by the expansion processes is 5 out of 1000, the copy number of each of the 5 clones increases. Specifically, 10 rounds of selection are performed during the primary response, with the top x = 58% of the sequences chosen at each round. This procedure mimics the concentration expansion factor of 10 3 ≈ 2 10 in the primary response and leads to 0.5% diversity of the memory repertoire, because 0.58 10 ≈ 0.5% and 10 days of doubling leads to a concentration expansion of 2 10 = 1024. Thus, the repertoire killing the tumor consists of these 5 sequences, each at an average copy number of 200. After 10 rounds, about 1% of the T cells in the human immune system will be specific for the cancer epitopes. Each additional round will double this number, up to a maximum of 100%, since the total number of memory T cells is roughly constant. We will look at the effect of an additional couple of rounds, beyond the 10 rounds that leads to the physiological 1000 × concentration expansion.
There cannot be more than a couple of additional rounds, because the percentage of T cells specific for a disease does not typically exceed 1-5% in the human immune system [56] .
For polytopic vaccination, the different epitopes are injected in different physical locations and evoke an immune response that evolves independently in different lymph nodes until mixing round, after which the lymph system is well-mixed. This is calculated by performing a response against each of the four epitopes independently, with selection among 10 3 TCRs for each epitope, until mixing round. After the mixing round, T cells from one of the V lymph nodes are able to renter the other V − 1 lymph nodes. So, all V lymph nodes will begin to contain roughly similar repertoires of T cells. Thus, we consider a representative lymph node, with a T cell capacity equal to that of one of the V lymph nodes, and in which the T cells from all V lymph nodes may be present. In other words, at the mixing round, 10
3 TCRs are randomly chosen from the V × 10 3 partially evolved TCRs. These 10
3
TCRs are then evolved from mixing round until day 10. During the period from mixing round until day 10, the TCRs are ranked by the sum of the V binding constants when the top 58% selection is performed. In this way, we compute the independent response in different lymph nodes against each epitope that occurs early on and the combined response in a typical lymph node against all epitopes that occurs after the lymph system has mixed. To make comparison with Fig. 1 , the conversion between mixing day and mixing round is needed. Since T cells divide 1-3 times a day [1] , mixing round will be mixing day divided by the factor of 1-3. For this reason, we expect mixing round to be near the maximum value of 10 for polytopic vaccination. Singlesite vaccination is computed with mixing round = 0, and polytopic vaccination is computed with mixing round = 9. Implementation of our theory proceeds by computational simulation of the generalized NK model. First, the peptide and the altered peptide ligands are created. Then, the random terms such as the secondary structural types of the subdomains, the σ values, the binding sites, and the interaction sites of the generalized NK model are determined. Then the fraction and identity of the T cell repertoire that responds well to each epitope is identified. We take N size = 10 8 /10 5 = 1000 distinct T cells to participate in the naive response against each epitope. Then the values of the constants a and b in (6) are calculated. The primary response of 10 rounds of selection is then carried out. Finally, the secondary response, a linear combination of 10 rounds from the naive pool and 3 rounds from the memory pool, with the fraction of each depending on the relative binding constants for the altered peptide, is carried out. This secondary response is not modeled in the present application to cancer.
Tumor-Related Parameters
For each epitope, the sequence, model, and VDJ selection pools differ by p epitope [36] , where p epitope = [(non-conservative + To generate results, an average over many instances of these random epitope sequences, models, and VDJ selection pools that differ by p epitope is taken. That is, the V different cancer epitopes were chosen so that they differ by the requisite p epitope . For each instance of the ensemble, V new random epitopes were generated. We display results for correlated and uncorrelated epitopes by using the two values of p epitope = 0.15, 1.00. Figure 5a shows the typical level of immunodominance that occurs for a traditional two-component vaccine in the 1591-A/B system [19] . Figure 5b shows the reduced immunodominance that occurs if each component of the vaccine is injected into a different physical location, with a different draining lymph node. Briefly, there are two cancer strains. One is strain A and the other is strain B. It is assumed that the response to each strain is to a single epitope and that the two epitopes are unrelated. The epitope on strain A is dominant to the epitope on strain B. In Fig. 5a , epitope A and epitope B were injected together in the same flank of one animal, while they are injected in different flanks of one animal in Fig. 5b . After 1 month, spleen cells from the animal were restimulated with epitope A or B and the T cells assayed for specific lysis.
Results
While epitope A is dominant, there can be a significant immune response to epitope B. In particular, if vaccination is done against epitope B, there is response only against epitope B, Fig. 6b . Conversely, if vaccination is done against epitope A, there is response only against epitope A, Fig. 6a . If singlesite vaccination is done against both A and B, there is response primarily against A, Fig. 5a . Conversely, if polytopic vaccination is done against both A and B, there is a significant response against both A and B, Fig. 5b. 
Discussion
To compare single-site and polytopic vaccination, we show in Fig. 7ac The specific lysis arising from the T cell repertoire induced if two completely different (pepitope = 1) cancer epitopes (A,B) are injected into the same site. Epitope A is dominant. Comparison between theory with no adjustable parameters (th) and experiment (exp) [19] . Two sets of experimental data for epitope B are shown. (b) The specific lysis arising from the T cell repertoire induced if two cancer epitopes are injected into different sites, with different draining lymph nodes. Note the reduced immunodominance. Data contain ∼+20% background, which was subtracted from the clearance probability of the subdominant epitopes is an especially important mechanism for immune evasion by mutation: If the dominant epitope mutates and is lost, the response to the remaining epitopes is very low. This effect is shown in Table 2 . The diversity of the TCR repertoire plays a key role in inducing a longlasting and broad immune response [38] . Some insight into the diversity of the T cell repertoire can be gained from the histograms of the T cell reper- Curve is from the model, and data are from [19] . Data contain ∼+20% background, which was subtracted from the clearance probability toire recognition of each epitope, Fig. 7bd . This figure shows that the T cell repertoire of the immune response is shaped by the epitopes presented on the tumor cell. This figure also shows that the method of delivering the vaccine affects the T cell repertoire induced by the immune response, Fig. 7bd . In particular, polytopic vaccination leads to a broader and more robust repertoire, Fig. 7bd . This broader response of the polytopic vaccination, in turn, leads to less immunodominance, Fig. 5 .
The solid nature of tumors presents some challenges to immune control, but also some opportunities. It may be difficult, for example, for T cells to enter the solid tumor. Conversely, high intensity focused ultrasound can disrupt solid tumors and can enhance systemic antitumor cellular immunity [57] . Although the exact mechanism of this enhancement is unknown, one possi- Energy, U , is related to the binding constant, K, by (6) . Here E/T = 3.0 bility is that the fragments of tumor after destruction can travel to different lymph nodes and thus induce a diverse TCR repertoire, in similar fashion to polytopic vaccination. More prosaically, the physical disruption of the tumor can allow easier entry of the T cells. Another feature of solid tumors is the enhanced probability of uptake of large proteins, due to the highly porous capillaries in tumors [58] . By using this property, stimulants of T cell activity may be localized to the tumors. The concentration of such stimulants could be increased further by conjugation with elastin-like polypeptides that undergo 
Conclusions
In this chapter, we have described a possible mechanism by which polytopic vaccination overcomes immunodominance in therapeutic T cell vaccines for cancer. Our approach captured the recognition characteristics between the TCRs and tumor, the primary dynamics due to the TCR resource competition, and elimination of tumor cells by effector TCRs. The ability of our model to reproduce standard cancer immunological data was demonstrated. Multicomponent polytopic vaccination was shown to be a promising protocol to mitigate immunodominance. Therapeutic cancer vaccine design is undergoing a resurgence not only because of its clinical importance, but also because of the many fascinating associated scientific issues. We hope that by suggesting here the mechanism of action for polytopic vaccination to be independent concentration expansion of T cells in distinct lymph, additional studies making use of the polytopic protocol will be spurred.
